Conditions: Secondarily Infected Traumatic Lesions (SITL) Impetigo
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 20
Healthy volunteers: no

Brief summary:
A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic Lesions (SITL). A total of 20 patients will be enrolled.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: 2% TD1414 Cream
Intervention descriptions: intervention 1: Application 3 times daily for 7 days

Protocol document: